CN101163485A - 用包封于脂质体的多柔比星治疗晚期卵巢癌的方法 - Google Patents

用包封于脂质体的多柔比星治疗晚期卵巢癌的方法 Download PDF

Info

Publication number
CN101163485A
CN101163485A CNA2006800130738A CN200680013073A CN101163485A CN 101163485 A CN101163485 A CN 101163485A CN A2006800130738 A CNA2006800130738 A CN A2006800130738A CN 200680013073 A CN200680013073 A CN 200680013073A CN 101163485 A CN101163485 A CN 101163485A
Authority
CN
China
Prior art keywords
administering
comprises administering
ovarian cancer
administering comprises
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800130738A
Other languages
English (en)
Chinese (zh)
Inventor
R·D·阿尔瓦雷斯
M·J·小斯特劳恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CN101163485A publication Critical patent/CN101163485A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2006800130738A 2005-04-21 2006-04-20 用包封于脂质体的多柔比星治疗晚期卵巢癌的方法 Pending CN101163485A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67418805P 2005-04-21 2005-04-21
US60/674,188 2005-04-21

Publications (1)

Publication Number Publication Date
CN101163485A true CN101163485A (zh) 2008-04-16

Family

ID=36811891

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800130738A Pending CN101163485A (zh) 2005-04-21 2006-04-20 用包封于脂质体的多柔比星治疗晚期卵巢癌的方法

Country Status (11)

Country Link
US (1) US20070026060A1 (enExample)
EP (1) EP1874324A1 (enExample)
JP (1) JP2008538584A (enExample)
KR (1) KR20080008367A (enExample)
CN (1) CN101163485A (enExample)
AU (1) AU2006238877A1 (enExample)
BR (1) BRPI0609939A2 (enExample)
CA (1) CA2605669A1 (enExample)
IL (1) IL186699A0 (enExample)
MX (1) MX2007013056A (enExample)
WO (1) WO2006116341A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
EP3693473B1 (en) 2011-06-17 2025-02-19 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
DK3415915T3 (da) 2012-02-23 2024-11-04 Childrens Medical Center Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013273466B2 (en) 2012-06-07 2018-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2946251T3 (es) 2014-08-15 2023-07-14 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment

Also Published As

Publication number Publication date
MX2007013056A (es) 2008-04-07
AU2006238877A1 (en) 2006-11-02
JP2008538584A (ja) 2008-10-30
BRPI0609939A2 (pt) 2010-05-11
WO2006116341A1 (en) 2006-11-02
CA2605669A1 (en) 2006-11-02
US20070026060A1 (en) 2007-02-01
KR20080008367A (ko) 2008-01-23
EP1874324A1 (en) 2008-01-09
IL186699A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
Scholl et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6
Hasovits et al. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics
Gandara et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non–small-cell lung cancer: phase II Southwest Oncology Group Study S9504
Ye et al. Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review
Howell et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Yun et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
Alemzadeh et al. Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
US20070026060A1 (en) Method for treating advanced ovarian cancer
Li et al. Comparative effectiveness of pemetrexed-platinum doublet chemotherapy with or without bevacizumab as first-line therapy for treatment-naive patients with advanced nonsquamous non–small-cell lung cancer in China
Koper et al. Advancements in cancer chemotherapy
Kunisaki et al. Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer
Osaki et al. Feasibility of induction chemotherapy using bronchial arterial infusion for locally advanced non-small cell lung cancer: a pilot study
WO2006032136A1 (en) Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
US20020110601A1 (en) Antineoplastic platinum therapeutic method and composition
Fujiwara et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study
Recchia et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
Chiani et al. Enhanced antitumor effect of targeted nanoliposomal bleomycin
De Souza et al. Nanoformulations for therapy of pancreatic and liver cancers
Vermorken The role of intraperitoneal chemotherapy in epithelial ovarian cancer
Verma et al. Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study
CN117015343A (zh) 用于持续释放放射性药剂的组合物和相关方法以及其应用
Rosell et al. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review
Kavanagh et al. Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix.
Yamada et al. Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan
CN116407548A (zh) 一种蒽环类抗肿瘤药和铂类抗肿瘤药的组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080416